SCHEMBL25754749

SCHEMBL25754749

CC#CC(O)CN(C)CCCOCCCN1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 15/20 0.38
HRH1 P35367 3/20 0.38
SLC6A2 P23975 2/20 0.38
KCNH2 Q12809 2/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CACNA1C Q13936 1/20 0.38
SCN5A Q14524 1/20 0.38
CHRM4 P08173 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754735 0.97 HRH3 (0.36) HRH3HRH1SLC6A2KCNH2CHRM2
SCHEMBL25754761 0.89 HRH3 (0.36) HRH3HRH1SLC6A2KCNH2CHRM2
SCHEMBL25754763 0.88 SIGMAR1 (0.35) HRH3HRH1SLC6A2KCNH2CHRM2
SCHEMBL25754756 0.85 SLC6A3 (0.36) HRH3SLC6A2SLC6A4SLC6A3SIGMAR1
SCHEMBL25754760 0.84 HRH3 (0.36) HRH3HRH1SLC6A2KCNH2CHRM2
SCHEMBL25754728 0.82 SLC6A3 (0.36) SLC6A2SLC6A4SLC6A3SIGMAR1CYP3A4
SCHEMBL25754744 0.82 SIGMAR1 (0.35) HRH3SLC6A2SLC6A4SIGMAR1
SCHEMBL25754616 0.79 HRH3 (0.40) HRH3HRH1SLC6A2KCNH2CHRM2
SCHEMBL25754611 0.79 HRH3 (0.40) HRH3HRH1SLC6A2KCNH2CHRM2
SCHEMBL25754349 0.78 SPHK1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 HRH3 1596/4885HRH1 1557/4885SLC6A2 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.